secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001683168-24-005903
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma Q2 revenue $9.3M (+67% YoY); net loss narrows 45% to $(494K)
-------------------------------------------------------------------------------

- Q2 gross revenue $9,303,067, up 67% from $5,560,865 in Q2 2023.
- Net loss for Q2 2024 was $(494,300) vs $(902,108) in Q2 2023, a 45% improvement.
- YTD revenue $16,844,113, up 61% from $10,454,918; YTD net loss $(1,778,101) improved 32%.
- Sequential Q2 sales grew 23% over Q1 2024 sales of $7,541,046.
- Shareholders' equity $23,489,865, up 11% from Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824005903/0001683168-24-005903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824005903/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer